Making oncology global with the WIN consortium

The translational element of the WIN consortium

How the WIN consortium achieves its goals

Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive patients (pts) with PD-L1 advanced NSCLC

Entrectinib in NTRK fusion-positive non-small cell lung cancer

Using CT imaging to find radiomic signatures in surgically resected NSCLC

The role of afatinib in patients with EGFR NSCLC

ADMIRAL: Gilteritinib as treatment for patients with relapsed or refractory acute myeloid leukaemia

Efficacy and immune correlates of the SRA737 plus LDG regimen in combination with anti-PD-L1 in an SCLC model

TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on EGFR-TKI

Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies

Umbralisib as a monotherapy in patients with relapsed/refractory marginal zone lymphoma